External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology EASDEC 2024
Roche and Genentech at

EASDEC 2024

May 30 - June 01
Milan, Italy
easdec.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
May 31 / Roche and Genentech
Real-world treatment patterns and visual outcomes in the first 12 months of faricimab▼ use in DME: UK FARWIDE-DME study
Analysis of the multi-center FARWIDE real-world study on faricimab▼ uptake and use in patients with DME from the UK following launch in 2022. Data are presented for treatment-naive and previously treated eyes with 12 months of follow up. Most eyes were previously treated with anti-VEGF and most of these patients received aflibercept. Treatment naive eyes achieved visual gains during the follow up period, while previously treated eyes showed stable visual acuity.
Ophthalmology Diabetic Macular Edema EASDEC-2024
11:00 AM
Duration 115mins Milan, Italy
Real-world treatment patterns and visual outcomes in the first 12 months of faricimab use in DME: UK FARWIDE-DME study
Christine Kiire
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.